AGM
CTIC

Alpine Global Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Alpine Global Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,663
Closed -$59K – 714
2022
Q1 		$59K Buy
+12,663
New +$37.8K 0.01% 305
2021
Q1 		– Sell
-32,720
Closed -$105K – 430
2020
Q4 		$105K Buy
+32,720
New +$109K 0.02% 154
2016
Q3 		– Sell
-17,559
Closed -$60K – 238
2016
Q2 		$60K Buy
+17,559
New +$80.6K 0.03% 159

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Alpine Global Management's CTIC Position: Q2 2022 in Review

Alpine Global Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2022, closing a stake of 12,663 shares — an estimated $59K sold.

Alpine Global Management first reported a position in CTIC in Q2 2016 and held it in 3 quarters. The position peaked at $105K in Q4 2020. 119 funds tracked by Wall St. Rank hold CTIC as of Q2 2022.

  • Alpine Global Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2022 after selling out during the quarter.
  • Alpine Global Management sold 12,663 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2022, an estimated $59K.
  • Alpine Global Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2016 and held it in 3 quarters.
  • Alpine Global Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $105K in Q4 2020.
  • 119 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2022.

Based on Alpine Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.